find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
352
Clinical Trials
Breast Cancer Clinical Trials
Phase III
Enrolling
nct/study# NCT07060807 / MK1022-016
An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy versus Treatment of Physician’s Choice in Hormone Receptor positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04)
Learn More
Breast Cancer Clinical Trials
Phase III
Enrolling
nct/study# NCT06841354 / MK2870-011
A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (sac-TMT, MK-2870) as a Monotherapy and in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less than 10 (TroFuse 11)
Learn More
Gastrointestinal (GI) Oncology
N/A
Enrolling
nct/study# N/A / CELL-FREE-DNA-MOLECULAR-PROF
Integrating Cell-Free DNA Molecular Profiles with Clinical Metadata to Inform Early-Stage Colorectal and Breast Cancer Outcomes
Learn More
Gastrointestinal (GI) Oncology
Phase II
Enrolling
nct/study# NCT06015724 / DARANIVOVAX-IST
A Phase 2 Study Evaluating the Efficacy of Anti-CD38 antibody in Combination with KRAS vaccine and Anti-PD-1 Antibody in Subjects with Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer
Learn More
Gastrointestinal (GI) Oncology
N/A
Enrolling
nct/study# N/A / HVSNONH-GEDJC
Clinical, Molecular and Prognostic Differences between Hispanic (H) and non-Hispanic (non-H) patients with gastroesophageal (GEJ)/gastric cancers (GC): Molecular classification by Multiplex Immunohistochemistry (mIHC) and Next-generation sequencing (NGS)
Learn More
Gastrointestinal (GI) Oncology
Phase III
Enrolling
nct/study# NCT06997497 / MK1084-012
A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012)
Learn Morewe are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.